HBC Hofseth Biocare

Hofseth Biocare ASA: SHARE CAPITAL DECREASE REGISTERED – NEW PAR VALUE

Hofseth Biocare ASA: SHARE CAPITAL DECREASE REGISTERED – NEW PAR VALUE

Reference is made to the decision by the general meeting of Hofseth BioCare ASA (the "Company") on 25 May 2020 to decrease the share capital with NOK 325,783,142.19 through a reduction of the par value of the shares of the Company from NOK 1 to NOK 0.01. The number of outstanding shares in the Company is not affected by the share capital decrease and remains unchanged.

The share capital decrease has now been registered with the Norwegian Register of Businesses. The new share capital of the Company is NOK 3,290,738.81 divided by 329,073,811 shares, each with a par value of NOK 0.01.

The share capital decrease will be registered in the VPS as soon as practically possible.

For further information, please contact:

Jon Olav Ødegård, CFO of Hofseth BioCare ASA

Phone:  966

E-mail:

About Hofseth BioCare ASA:

HBC is a Norwegian biotech company that develops high-value ingredients and finished products. The ingredients are in various stages of discovery and preclinical development in collaboration with multiple clinics and university research labs in several countries. Lead preclinical and clinical candidates are in development toward treatment for iron-deficiency anemia, Gastro-Intestinal Inflammation (NEC/IBS/UC), prediabetes, age-related sarcopenia and osteoarthritis.

The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC can preserve the quality of lipids, proteins and calcium from fresh salmon off-cuts. Hofseth BioCare's headquarters are in Ålesund, Norway with branches in Oslo, London, Zürich, Chicago, Menlo Park and Tokyo.

HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC". More information about Hofseth BioCare at hofsethbiocare.com and facebook.com/hofsethbiocare



This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

EN
12/08/2020

Underlying

HBCHofseth Biocare

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hofseth Biocare

 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: ProGo, the world’s first consumer health GLP-1 & ...

Hofseth Biocare ASA: ProGo, the world’s first consumer health GLP-1 & GIP receptor agonist with muscle mass protection via inhibition of Myostatin and Activin A pathways HBC has today released a whitepaper demonstrating how its bioactive peptide ingredient ProGo® uniquely provides complete GLP-1 support. To maximize the effect of GLP-1 therapy, lean muscle mass needs to be protected to optimize the benefits of weight loss and support a healthy metabolism. ProGo®️ addresses these needs through its unique triple action properties: highly absorbable protein with a complete amino acid profi...

September 9, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: HBC onboards former Head of Nestle Health Science...

Hofseth Biocare ASA: HBC onboards former Head of Nestle Health Science Asia, Oceania, Middle East and Africa Region, Paul Bruhn HBC is delighted to announce the appointment of Paul Bruhn as Head of New Business Development. Mr Bruhn has over 25 years’ experience in healthcare and the medical nutrition space spanning Novartis Medical Nutrition and Nestle Health Science. He has been leading businesses across multiple geographies including Japan, Korea, India, Middle East, Singapore, Canada, Switzerland and Australia and hence has an excellent overlap with corporates focused on developing the...

September 4, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: SECOND QUARTER 2025 FINANCIAL REPORT

Hofseth Biocare ASA: SECOND QUARTER 2025 FINANCIAL REPORT HBC recorded total operating revenues of NOK 68.4 million in the second quarter of 2025, compared to NOK 80.4 million in the same period last year. Net operating revenues were NOK 67.8 million, compared to NOK 72.2 million in the same quarter last year. Total operating revenue for the first six months of 2025 was NOK 129.3 million (NOK 132.8 million). EBITDA for the quarter was negative NOK 5.4 million, compared to NOK -2.0 million in Q2 2024. The first six months was negative NOK 25.3 million (NOK-18.2 million) The Operational EBIT...

August 22, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: HBC’s ProGo® has won Ingredient of the Year for H...

Hofseth Biocare ASA: HBC’s ProGo® has won Ingredient of the Year for Healthy Aging at the prestigious Nutraingredients USA awards ceremony in Chicago According to the judges, the winning factors placing ProGo® well ahead of the competition are its unique ability to activate GLP-1 and GIP receptors, coupled with its unrivalled sustainability credentials including Upcycled Certified by WFCF (Where Food Comes From). Most significantly, these benefits are supported and evidenced through two clinical studies demonstrating weight loss with ProGo®. ProGo® Bioactive Peptides optimize the metabolis...

July 16, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: Annual General Meeting completed

Hofseth Biocare ASA: Annual General Meeting completed Hofseth BioCare ASA held its Annual General Meeting on 23 May 2025. All proposals were resolved as presented in the notice issued on 2 May 2025. The minutes from the Annual General Meeting are attached. For further information, please contact: Jon Olav Ødegård, CEO at HBC Phone: E-mail: About Hofseth BioCare ASA: HBC is a Norwegian consumer and pet health company founded on the core values of sustainability, optimal utilization of natural resources and full traceability. It upcycles the side streams of the salmon industry by takin...

May 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch